Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies. The new data will be featured in two oral presentations and five poster presentations at the 52nd American Society of Hematology (ASH) Annual Meeting being held December 4-7, 2010 in Orlando, FL.

Details regarding the presentations are listed below, and full abstracts can be accessed from the ASH website at www.hematology.org.

Oral Presentations

CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 Delta, Demonstrates Clinical Activity and Pharmacodynamic Effects in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  • Presenter: Richard R. Furman, M.D., Weill Medical College of Cornell University, New York, NY
  • Date/Time: Sunday, December 5, 2010; 4:30 p.m., Eastern Time
  • Location: Orange County Convention Center, Valencia D
  • Session: CLL - Therapy, Excluding Transplantation: Novel Agents and New Approaches
  • Abstract number: 55

Phosphoinositide 3-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurselike cells (NLC), in Chronic Lymphocytic Leukemia

  • Presenter: Julia Hoellenriegel, Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX
  • Date/Time: Sunday, December 5, 2010; 5:45 p.m., Eastern Time
  • Location: Orange County Convention Center, Valencia B/C
  • Session: CLL - Biology and Pathophysiology, Excluding Therapy
  • Abstract number: 48

Poster Presentations

Clinical Safety and Activity in a Phase 1 Study of CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 Delta, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

  • Presenter: Brad Kahl, M.D., University of Wisconsin, Madison, WI
  • Date/Time: Saturday, December 4, 2010; 5:30-7:30 p.m., Eastern Time
  • Location: Orange County Convention Center, Hall A3/A4
    Poster Board: I-757
  • Session: Lymphoma - Chemotherapy, Excluding Pre-Clinical Models: Poster I
  • Abstract number: 1777

A Phase 1 Study of CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 Delta, in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory B-Cell Malignancies

  • Presenter: Ian W. Flinn, M.D., Ph.D., Sarah Cannon Research Institute, Nashville, TN
  • Date/Time: Sunday, December 5, 2010; 6:00-8:00 p.m., Eastern Time
  • Location: Orange County Convention Center, Hall A3/A4
    Poster Board: II-712
  • Session: Lymphoma - Chemotherapy, Excluding Pre-Clinical Models: Poster II
  • Abstract number: 2832

CAL-101, a Potent Selective Inhibitor of the P110 Delta Isoform of Phosphatidylinositol 3-Kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals from the Microenvironment in Cellular Models of Hodgkin Lymphoma

  • Presenter: Sarah A. Meadows, Calistoga Pharmaceuticals
  • Date/Time: Monday, December 6, 2010; 6:00-8:00 p.m., Eastern Time
  • Location: Orange County Convention Center, Hall A3/A4
    Poster Board: III-705
  • Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
  • Abstract number: 3926

Clinical Pharmacokinetics of CAL-101, a P110 Delta Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration in Healthy Volunteers and Patients with Hematological Malignancies

  • Presenter: Heather K. Webb, Ph.D., Calistoga Pharmaceuticals
  • Date/Time: Saturday, December 4, 2010; 5:30-7:30 p.m., Eastern Time
  • Location: Orange County Convention Center, Hall A3/A4
    Poster Board: I-754
  • Session: Lymphoma - Chemotherapy, Excluding Pre-Clinical Models: Poster I
  • Abstract number: 1774

The Role of Phosphatidylinositol 3-Kinase-Delta in the Immunomodulatory Effects of Lenalidomide in Chronic Lymphocytic Leukemia

  • Presenter: Sarah E. M. Herman, The Ohio State University, Columbus, OH
  • Date/Time: Saturday, December 4, 2010; 5:30-7:30 p.m., Eastern Time
  • Location: Orange County Convention Center, Hall A3/A4
    Poster Board: I-801
  • Session: Molecular Pharmacology, Drug Resistance: Poster I
  • Abstract number: 1821
Source:

Calistoga Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ultrasound technology breaks blood-brain barrier for glioblastoma treatment